Barbora Pejsova

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
TP53 mutations are frequently detected in patients with higher-risk myelodysplastic syndromes (MDS); however, the clinical impact of these mutations on the disease course of patients with lower-risk MDS is unclear. In this study of 154 lower-risk MDS patients, TP53 mutations were identified in 13% of patients, with prevalence in patients with del(5q)(More)
  • 1